Possibilities of using statins in comprehensive antitumor treatment

Frequency of atherosclerosis significantly increases with age, same as malignant tumor morbidity. Concurrent pathology (including in the cardiovascular system) affects selection of antitumor treatment limiting use of cardiotoxic (though highly effective) drugs. Statins are the main treatment for atherosclerosis but their study showed that regulation of cholesterol metabolism affects functioning of tumor cells. According to the results of clinical trial meta-analyses, regular use of statins decreases mortality in patients with bladder, prostate, renal, ovarian, lung, breast, and colorectal cancer both due to decreased risk of cardiovascular complications and increased effectiveness of antitumor drugs. In some studies, decreased risk of liver, esophageal, endometrial, renal, gastric, and pancreatic cancers was observed in patients taking statins. Antitumor effects of statins are supposedly mediated by decreased cholesterol production which is used by tumor cells for functioning and membrane synthesis. Additionally, statins inactivate RAS and RHO oncogenes by suppressing their isoprenylation, inhibit proliferation of tumor cells. Statins also contribute to activation of antitumor immunity, increased ferroptosis and autophagy. Statins activate apoptosis by interacting with mitochondrial procaspase 9, inhibit expression of toll-like receptors (TLR4), NF-κB, tumor necrosis factor α, interleukins 1β and 6, suppress the mTOR pathway. Therefore, multifaceted direct and indirect antitumor effects of statins show that these pharmaceuticals should be more intently considered as a component of antitumor therapy.

1. Rea I.M., Gibson D.S., McGilligan V. et al. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol 2018;9:586. DOI: 10.3389/fimmu.2018.00586

2. Dorsch M., Kowalczyk M., Planque M. et al. Statins affect cancer cell plasticity with consequences for tumor progression and metastasis. Cell Rep 2021;37(8):110056. DOI: 10.1016/j.celrep.2021.110056

3. Zhu P.F., Wang M.X., Chen Z.L., Yang L. Targeting the tumor microenvironment: a literature review of the novel anti-tumor mechanism of statins. Front Oncol 2021;11:761107. DOI: 10.3389/fonc.2021.761107

4. Roubin S.R., Cordero A. The two-way relationship between cancer and atherosclerosis. Rev Esp Cardiol (Engl Ed) 2019;72(6):487–94. DOI: 10.1016/j.rec.2018.12.010

5. Mladosievicova B., Petrikova L., Valaskova Z. et al. Atherosclerosis in cancer patients. Bratisl Lek Listy 2019;120(9):636–40. DOI: 10.4149/BLL_2019_105

6. Inno A., Chiampan A., Lanzoni L. et al. Immune checkpoint inhibitors and atherosclerotic vascular events in cancer patients. Front Cardiovasc Med 2021;8:652186. DOI: 10.3389/fcvm.2021.652186

7. Mensah S.A., Nersesyan A.A., Ebong E.E. Endothelial glycocalyx-mediated intercellular interactions: mechanisms and implications for atherosclerosis and cancer metastasis. Cardiovasc Eng Technol 2021;12(1):72–90. DOI: 10.1007/s13239-020-00487-7

8. Pomeshkin E.V., Bragin-Maltsev A.I., Pomeshkina S.A., Barbarash O.L. Prostate cancer and atherosclerosis. Urologiya = Urology 2020;5:122–6. (In Russ.) DOI: 10.1865/urology.2020.5.122-126

9. Filatova A.Yu., Vitsenya M.V., Potekhina A.V. et al. Atherosclerosis of brachiocephalic arteries and arterial stiffness in patients with breast cancer. Kardiologiya = Cardiology 2019;59(1S):43–52. (In Russ.). DOI: 10.18087/cardio.2585

10. Nehme F. An intimal relationship between atherosclerosis and colorectal cancer screening. Dig Dis Sci 2020;65(6):1588–9. DOI: 10.1007/s10620-020-06046-3

11. Bintein F., Yannoutsos A., Chatellier G. et al. Patients with atherosclerotic peripheral arterial disease have a high risk of lung cancer: systematic review and meta-analysis of literature. J Med Vasc 2021;46(2):53–65. DOI: 10.1016/j.jdmv.2020.12.005

12. Mullen P.J., Yu R., Longo J. et al. The interplay between cell signaling and the mevalonate pathway in cancer. Nat Rev Cancer 2016;16(11): 718–31. DOI: 10.1038/nrc.2016.76

13. Sheng B., Song Y., Zhang J. et al. Atorvastatin suppresses the progression of cervical cancer via regulation of autophagy. Am J Transl Res 2020; 12(9):5252–68.

14. Ling Y., Yang L., Huang H. et al. Prognostic significance of statin use in colorectal cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2015;94(25):e908. DOI: 10.1097/MD.0000000000000908

15. Manthravadi S., Shrestha A., Madhusudhana S. Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis. Int J Cancer 2016;139(6):1281–8. DOI: 10.1002/ijc.30185

16. Borgqujist S., Broberg P., Tojjar J., Olsson H. Statin use and breast cancer survival – a Swedish nationwide study. BMC Cancer 2019;19(1):54. DOI: 10.1186/s12885-018-5263-z

17. Chen Y., Li X., Zhang R. et al. Effercts of statin exposure and lung cancer survival: a meta-analysis of observational studies. Pharmacol Res 2019;141:357–65. DOI: 10.1016/j.phrs.2019.01.016

18. Luo Y., She D.L., Xiong H. et al. The prognostic effect of statin use on urologic cancers: an updated meta-analysis of 35 observational studies. Medicine (Baltimore) 2015;94(36):e1523. DOI: 10.1097/MD.0000000000001523

19. Zhong S., Zhang X., Chen L. et al. Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Cancer Treat Rev 2015;41(6):554–67. DOI: 10.1016/j.ctrv.2015.04.005

20. Nayan M., Punjani N., Juurlink D.N. et al. Statin use and kidney cancer survival outcomes: a systematic review and meta-analysis. Cancer Treat Rev 2017;52:105–16. DOI: 10.1016/j.ctrv.2016.11.009

21. Li X., Zhou J. Impact of postdiagnostic statin use on ovarian cancer mortality: a systematic review and meta-analysis of observational studies. Br J Clin Pharmacol 2018;84(6):1109–20. DOI: 10.1111/bcp.13559

22. Jeong G.H., Lee K.H., Kim J.Y. et al. Effect of statin on cancer incidence: an umbrella systematic review and meta-analysis. J Clin Med 2019;8(6):819. DOI: 10.3390/jcm8060819

23. Zhang Y., Liang M., Sun C. et al. Statin use and risk of pancreatic cancer: an updated meta-analysis of 26 studies. Pancreas 2019;48(2):142–50. DOI: 10.1097/MPA.0000000000001226

24. Desai P., Wallace R., Anderson M.L. et al. An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women’s Health Initiative. Gynecol Oncol 2018;148 (3):540–6. DOI: 10.1016/j.ygyno.2018.01.006

25. Chou Y.C., Lin C.H., Wong C.S. et al. Statin use and the risk of renal cell carcinoma: national cohort study. J Investig Med 2020;68(3):776–81. DOI: 10.1136/jim-2019-001209

26. You H.S., You N., Lee J.W. et al. Inverse association between statin use and stomach cancer incidence in individuals with hypercholesterolemia, from the 2002–2015 NHIS-HEALS date. Int J Environ Res Public Health 2020;17(3):1054. DOI: 10.3390/ijerph17031054

27. Ding X., Zhang W., Li S., Yang H. The role of cholesterol metabolism in cancer. Am J Cancer Res 2019;9(2):219–27.

28. Gabitova L., Gorin A., Astsaturov I. Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res 2014;20(1):28–34. DOI: 10.1158/1078-0432.CCR-13-0122

29. Bathaie S.Z., Ashrafi M., Azizian M., Tamanoi F. Mevalonate pathway and human cancers. Curr Mol Pharmacol 2017;10(2):77–85. DOI: 10.2174/1874467209666160112123205

30. Thurnher M., Nussbaumer O., Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 2012;18(13):3524–31. DOI: 10.1158/1078-0432.CCR-12-0489

31. Yao X., Xie R., Cao Y. et al. Simvastatin induced ferroptosis for triple-negative breast cancer therapy. J Nanobiotechnology 2021;19(1):311. DOI: 10.1186/s12951-021-01058-1

32. Ampuero J., Romero-Gomez M. Prevention of hepatocellular carcinoma by correction of metabolic abnormalies: role of statins and metformin. World J Hepatol 2015;7(8):1105–11. DOI: 10.4254/wjh.v7.i8.1105

33. Fliedner S.M., Engel T., Lendvai N.K. et al. Anti-cancer potential of MAPK pathway inhibiton in paragangliomas-effect of different statins on mouse pheochromacytoma cells. PLoS One 2014;9(5):e97712. DOI: 10.1371/journal.pone.0097712

34. Hu M.B., Zhang J.W., Gao J.B. et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastruct Pathol 2018;42(5):409–15. DOI: 10.1080/01913123.2018.1522406

35. Kamata T., Dujaily E.A., Alhamad S. et al. Statins mediate antiand pro-tumorigenic functions by remodeling the tumour microenvironment. Dis Model Mech 2022;15(2):dmm.049148. DOI: 10.1242/dmm.049148

36. Cordes T., Metallo C.M. Statins limit coenzyme Q synthesis and metabolically synergize with MEK inhibition in pancreatic tumors. Cancer Res 2020;80(2):151–2. DOI: 10.1158/0008-5472.CAN-19-3415

37. Longo J., Pandyra A.A., Stachura P. et al. Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. Mol Oncol 2020;14(10):2533–45. DOI: 10.1002/1878-0261.12775

38. Mangelinck A., Habel N., Mohr A. et al. Synergistic anti-tumor effect of simvastatin combined to chemotherapy in osteosarcoma. Cancer (Basel) 2021;13(22):5869. DOI: 10.3390/cancers13225869

39. Wojtkowiak J.W., Fouad F., LaLonde D.T. et al. Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. J Pharmacol Exp Ther 2008;326(1):1–11. DOI: 10.1124/jpet.107.135830